JSKN016

JSKN016 is a bispecific antibody-drug conjugate (ADC) developed by Alphamab Oncology using a proprietary Glycan-specific conjugation platform. It simultaneously targets HER3 (Human epidermal growth factor receptor 3) and TROP2 (Trophoblast cell surface antigen 2) on tumor cells. Upon binding to these antigens, JSKN016 is internalized via target-mediated endocytosis, where it releases a cytotoxic topoisomerase I inhibitor (TOPIi), inducing apoptosis in HER3- or TROP2-positive tumor cells. The released inhibitor can also permeate neighboring antigen-negative tumor cells, exerting a bystander effect and further inhibiting tumor growth. JSKN016 is currently being evaluated in phase I clinical trials for the treatment of advanced malignant solid tumors in China.